ReviewWorld journal of urology2005
Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
Review in World journal of urology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 99 citations in OpenAlex.
- The multiple roles and therapeutic potential of clusterin in non-small-cell lung cancer: a narrative review.Translational lung cancer research · 2021Review
- Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma.World journal of gastroenterology · 2015Review
- Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.Oncotarget · 2014Article
- Hypoxia inducible factor-1α directly regulates nuclear clusterin transcription by interacting with hypoxia response elements in the clusterin promoter.Molecules and cells · 2014Article
- Apoptosis and molecular targeting therapy in cancer.BioMed research international · 2014Review
- Novel non-AR therapeutic targets in castrate resistant prostate cancer.Translational andrology and urology · 2013Review
- Cytoplasmic Clusterin expression correlates with pancreatic neuroendocrine tumor size and pathological stage.Pancreas · 2013Article
- The role of heat shock proteins in bladder cancer.Nature reviews. Urology · 2013Review
- Article
- Potential use of custirsen to treat prostate cancer.OncoTargets and therapy · 2013Article
- Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.Journal of experimental & clinical cancer research : CR · 2012Article
- Clusterin and chemotherapy sensitivity under normoxic and graded hypoxic conditions in colorectal cancer.Journal of gastrointestinal cancer · 2012Article
- mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer.Journal of cellular physiology · 2012Article
- Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.Journal of experimental & clinical cancer research : CR · 2011Article
- Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2011Article
- Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.Prostate cancer and prostatic diseases · 2011Review
- Future directions in castrate-resistant prostate cancer therapy.Clinical genitourinary cancer · 2010Review
- Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder.Pathology oncology research : POR · 2010Article
- Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010Article
- Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread.Oncogene · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery and targeting of genes mediating androgen-independence may lead to the development of novel therapies that delay progression of hormone refractory prostate cancer (HRPC). Clusterin is a stress-associated cell survival gene that increases after androgen ablation. Here, we review clusterin's functional role in apoptosis and the use of antisense oligonucleotides (ASOs) against clusterin to enhance apoptosis in prostate cancer models. Immunostaining of tissue microarrays constructed from untreated and post-hormone treated radical prostatectomy specimens confirm that clusterin is highly expressed in virtually all HRPC cells, 80% of prostate cancer cells after neoadjuvant hormone therapy, but is low or absent (<20%) in untreated specimens. Overexpression of clusterin in LNCaP cells confers resistance to both androgen ablation and chemotherapy. Clusterin ASOs reduced clusterin levels in a dose-dependent and sequence-specific manner. Adjuvant treatment with murine clusterin ASOs after castration of mice bearing Shionogi tumors decreased clusterin levels, accelerated apoptotic tumor regression, and significantly delayed the recurrence of androgen-independent tumors. A human clusterin ASO targeting the translation initiation site and incorporating MOE-gapmer backbone (OGX-011) synergistically enhanced the cytotoxic effects of paclitaxel in human xenografts of prostate, renal cell, bladder, and lung cancer. Clusterin, is an anti-apoptosis protein upregulated in an adaptive cell survival manner by androgen ablation and chemotherapy that confers resistance to various cell death triggers. Suppression of clusterin levels using ASOs enhances cell death following treatment with androgen ablation, radiation, and chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.